

## GENE FAMILIES ASSOCIATED WITH LIVER CANCER

### TECHNICAL FIELD

5           The invention relates generally to the changes in gene expression in liver tissue from cancer patients who concurrently suffer from cirrhosis or hepatitis. The invention specifically relates to human gene families which are differentially expressed in hepatic carcinoma tissue, compared to inflamed or cirrhotic liver tissue, and in other malignant neoplasms.

10

### BACKGROUND ART

#### Liver Disease

15           Generally, liver disease is classified as a disorder that causes the liver to malfunction or cease functioning all together. Cirrhosis, for example, is a group of chronic liver diseases in which liver cells are damaged and then replaced with scar tissue, thereby decreasing the amount of normal liver tissue. While it is most often caused by alcohol abuse, patients with hepatitis infections and other biliary diseases can also develop cirrhosis. Chronic hepatitis-B infection, hepatitis-C infection, and cirrhosis  
20           have all been shown to have strong associations with primary liver cancer, although the mechanisms involved are still not fully understood (Wu *et al.*, (2001) *Oncogene* 20:3674-3682). About 10-20% of chronic hepatitis-B infections result in primary liver cancer. Other factors such as alcohol consumption, poor nutrition and aflatoxins are also linked to the development of primary liver cancer and cirrhosis.

25           Cirrhosis of the liver is characterized by widespread nodules combined with fibrosis. Damaged or dead liver cells are replaced by fibrous scar tissue, which to leads to fibrosis. Liver cells regenerate in an abnormal pattern, producing nodules surrounded by fibrous tissue. The fibrosis and nodule formation cause distortion and blockage of the liver's structural components, causing impaired blood flow and  
30           biochemical function.

In patients displaying overt symptoms, diagnosis of cirrhosis is usually easy, but cirrhosis may be difficult to detect in its early stages. Subtle changes occurring in the early stages include red palms, red spots on the upper body that blanch, hypertrophy of the parotid glands, fibrosis of the tendons in the palms and gynecomastia. X-rays and radioactive tracer tests may be effective, but diagnosis must often be by liver biopsy.

In contrast to the underlying pathology of cirrhosis, in primary liver cancer, liver cells become abnormal, grow out of control and form malignant tumors. This disease is also called hepatocellular carcinoma (HCC) or malignant hepatoma. Cancer that spreads to the liver from another part of the body as a result of metastasis is not the same disease. HCC is difficult to detect at an early stage because the symptoms are not specific. They include loss of appetite and weight, fever, fatigue and weakness. As the cancer progresses, pain may develop in the upper abdomen, extending to the back and right shoulder. Swelling or a palpable mass may also be present in the upper abdomen; along with jaundice and darkened urine. When the cancer metastasizes, it typically targets the lungs and brain.

Diagnosis of HCC may be made by blood tests, in particular, tests for tumor markers such as alpha-fetoprotein. About 50-70% of HCC patients show elevated levels of alpha-fetoprotein. Additional diagnostic methods include non-radioactive imaging (abdominal or chest x-rays, angiograms, CT scans and MRIs), liver scans using radioactive materials and liver biopsies. Treatment of HCC is often not successful, because detection is often too late, but methods include surgical removal of the cancer, chemotherapy and radiation, alone or in combination. Although HCC is not very common in the United States, it is very prevalent in parts of Asia and Africa, largely due to the higher incidence of infection with hepatitis viruses (<http://cis.nci.nih.gov/>; [http://cancer.med.upenn.edu/disease/liver/intro\\_liver.html](http://cancer.med.upenn.edu/disease/liver/intro_liver.html)).

### Molecular Changes in Liver Disease

Little is known about the molecular changes in liver cells associated with the development and progression of liver disease. Accordingly, there exists a need for the investigation of the changes in gene expression levels as well as the need for the

identification of new molecular markers associated with the development and progression of liver disease. Furthermore, if intervention is expected to be successful in halting or slowing down liver disease, means of accurately assessing the early manifestations of cirrhosis or HCC need to be established. Likewise, the development of therapeutics to prevent or stop the progression of liver disease relies on the identification of genes responsible for the cancerous transformation of liver cells and the growth of cancerous liver cells or the induction of tissue damage and scar formation associated with cirrhosis.

### DISCLOSURE OF THE INVENTION

The present invention is based on the discovery of new gene families, each designated LBFL302 and LBFL303, that are differentially expressed in hepatocellular carcinoma (HCC), compared to liver cirrhosis (LC) or chronic hepatitis (CH), and in other malignant neoplasms. The invention includes an isolated nucleic acid molecule selected from the group consisting of an isolated nucleic acid molecule comprising SEQ ID NO: 1, 3, 5 or 7, an isolated nucleic acid molecule encoding SEQ ID NO: 6 or 8, an isolated nucleic acid molecule that encodes a protein that is expressed in liver cancer and that exhibits at least about 95% nucleotide sequence identity over the entire contiguous sequence of SEQ ID NO: 5, an isolated nucleic acid molecule that encodes a protein that is expressed in liver cancer and that exhibits at least about 75% nucleotide sequence identity over the entire contiguous sequence of SEQ ID NO: 7, and an isolated nucleic acid molecule comprising the complement of any of the aforementioned nucleic acid molecules.

The present invention further includes the nucleic acid molecules operably linked to one or more expression control elements, including vectors comprising the isolated nucleic acid molecules. The invention further includes host cells transformed to contain the nucleic acid molecules of the invention and methods for producing a protein comprising the step of culturing a host cell transformed with a nucleic acid molecule of the invention under conditions in which the protein is expressed.

The invention further provides an isolated polypeptide selected from the group

consisting of an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 2, 4, 6 or 8, an isolated polypeptide comprising a fragment of at least 10 amino acids of SEQ ID NO: 2 or 4, an isolated polypeptide comprising conservative amino acid substitutions of SEQ ID NO: 2 or 4 and an isolated polypeptide comprising naturally occurring amino acid sequence variants of SEQ ID NO: 2 or 4. Polypeptides of the invention also include polypeptides with an amino acid sequence having at least about 50%, 60%, 70% or 75% amino acid sequence identity with the sequence set forth in SEQ ID NO: 2 or 4, preferably at least about 80%, more preferably at least about 90-95%, and most preferably at least about 95-98% sequence identity with the sequence set forth in SEQ ID NO: 2 or 4, and a protein having at least about 95% amino acid sequence identity with SEQ ID NO: 6 or 8.

The invention further provides an isolated antibody or antigen-binding antibody fragment that specifically binds to a polypeptide of the invention, including monoclonal and polyclonal antibodies.

The invention further provides methods of identifying an agent which modulates the expression of a nucleic acid molecule encoding a protein of the invention, comprising: exposing cells which express the nucleic acid molecule to the agent; and determining whether the agent modulates expression of said nucleic acid molecule, thereby identifying an agent which modulates the expression of a nucleic acid molecule encoding the protein.

The invention further provides methods of identifying an agent which modulates the level of or at least one activity of a protein of the invention, comprising: exposing cells which express the protein to the agent; and determining whether the agent modulates the level of or at least one activity of said protein, thereby identifying an agent which modulates the level of or at least one activity of the protein.

The invention further provides methods of identifying binding partners for a protein of the invention, comprising the steps of exposing said protein to a potential binding partner; and determining if the potential binding partner binds to said protein, thereby identifying binding partners for the protein.

The present invention further provides methods of modulating the expression of

a nucleic acid molecule encoding a protein of the invention, comprising the step of administering an effective amount of an agent which modulates the expression of a nucleic acid molecule encoding the protein. The invention also provides methods of modulating at least one activity of a protein of the invention, comprising the step of  
5 administering an effective amount of an agent which modulates at least one activity of the protein of the invention.

The present invention further includes non-human transgenic animals modified to contain the nucleic acid molecules of the invention, or non-human transgenic animals modified to contain the mutated nucleic acid molecules such that expression of the  
10 encoded polypeptides of the invention is prevented.

The present invention also includes non-human transgenic animals in which all or a portion of a gene comprising all or a portion of SEQ ID NO: 1, 3, 5, 7 or 9 has been knocked out or deleted from the genome of the animal.

The invention further provides methods of diagnosing liver cancer and other  
15 cancers, comprising the steps of acquiring a tissue, blood, urine or other sample from a subject and determining the level of expression of a nucleic acid molecule of the invention or polypeptide of the invention.

The invention further includes compositions comprising a diluent and a polypeptide or protein selected from the group consisting of an isolated polypeptide  
20 comprising the amino acid sequence of SEQ ID NO: 2, 4, 6, 8 or 10, an isolated polypeptide comprising a fragment of at least 10 amino acids of SEQ ID NO: 2, 4, 6, 8 or 10, an isolated polypeptide comprising conservative amino acid substitutions of SEQ ID NO: 2 or 4, naturally occurring amino acid sequence variants of SEQ ID NO: 2 or 4, an isolated polypeptide with an amino acid sequence having at least about 50%, 60%, 70%  
25 or 75% amino acid sequence identity with the sequence set forth in SEQ ID NO: 2 or 4, preferably at least about 80%, more preferably at least about 90-95%, and most preferably at least about 95-98% sequence identity with the sequence set forth in SEQ ID NO: 2 or 4, and a polypeptide having at least about 95% amino acid sequence identity with SEQ ID NO: 6, 8 or 10.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 Figure 1 is a hydrophobicity plot of the protein encoded by the open reading frame of LBFL302, variant BC4 (SEQ ID NO: 2). Analysis was performed according to the methods of Kyte-Doolittle and Goldman *et al.*

Figure 2 Figure 2 is a hydrophobicity plot of the protein encoded by the open reading frame of LBFL302, variant BC7 (SEQ ID NO: 4). Analysis was performed according to the methods of Kyte-Doolittle and Goldman *et al.*

Figure 3 Figure 3 is a hydrophobicity plot of the protein encoded by the open reading frame of LBFL303, clone GE6 (SEQ ID NO: 6). Analysis was performed according to the methods of Kyte-Doolittle and Goldman *et al.*

Figure 4 Figure 4 is a hydrophobicity plot of the protein encoded by the open reading frame of LBFL303, clone MB5 (SEQ ID NO: 8). Analysis was performed according to the methods of Kyte-Doolittle and Goldman *et al.*

Figure 5 Figure 5 is a hydrophobicity plot of the protein encoded by the open reading frame of LBFL303, clone IE4 (SEQ ID NO: 10). Analysis was performed according to the methods of Kyte-Doolittle and Goldman *et al.*

## BEST MODE FOR CARRYING OUT THE INVENTION

### I. General Description

The present invention is based in part on the identification of new gene families (LBFL302 and LBFL303) that are differentially expressed in cancerous human liver tissue, compared to inflamed or cirrhotic human liver tissue, and in other malignant neoplasms. These gene families correspond to the human cDNA of SEQ ID NOS: 1 and 3 (LBFL302), and SEQ ID NOS: 5, 7 and 9 (LBFL303).

The genes and proteins of the invention may be used as diagnostic agents or markers to detect liver cancer or to differentiate hepatic carcinoma from cirrhotic liver tissue in a sample. They can also serve as a target for agents that modulate gene expression or activity. For example, agents may be identified that modulate biological processes associated with tumor growth, including the hyperplastic process of liver cancer.

## II. Specific Embodiments

### A. The Proteins Associated with Liver Cancer

The present invention provides isolated proteins, allelic variants of the proteins, and conservative amino acid substitutions of the proteins. As used herein, the "protein" or "polypeptide" refers, in part, to a protein that has the human amino acid sequence depicted in SEQ ID NO: 2, 4, 6, 8 or 10. The terms also refer to naturally occurring allelic variants and proteins that have a slightly different amino acid sequence than that specifically recited above. Allelic variants, though possessing a slightly different amino acid sequence than those recited above, will still have the same or similar biological functions associated with these proteins.

As used herein, the family of proteins related to the human amino acid sequence of SEQ ID NO: 2, 4, 6, 8 or 10 refers to proteins that have been isolated from organisms in addition to humans. The methods used to identify and isolate other members of the family of proteins related to these proteins are described below.

The proteins of the present invention are preferably in isolated form. As used herein, a protein is said to be isolated when physical, mechanical or chemical methods are employed to remove the protein from cellular constituents that are normally associated with the protein. A skilled artisan can readily employ standard purification methods to obtain an isolated protein.

The proteins of the present invention further include insertion, deletion or conservative amino acid substitution variants of SEQ ID NO: 2, 4, 6, 8 or 10. As used herein, a conservative variant refers to alterations in the amino acid sequence that do not adversely affect the biological functions of the protein. A substitution, insertion or

deletion is said to adversely affect the protein when the altered sequence prevents or disrupts a biological function associated with the protein. For example, the overall charge, structure or hydrophobic/hydrophilic properties of the protein, in certain instances, may be altered without adversely affecting a biological activity. Accordingly, the amino acid sequence can be altered, for example to render the peptide more hydrophobic or hydrophilic, without adversely affecting the biological activities of the protein.

Ordinarily, the allelic variants, the conservative substitution variants, and the members of the protein family encoded by LBFL302 gene, will have an amino acid sequence having at least about 50%, 60%, 70% or 75% amino acid sequence identity with the sequence set forth in SEQ ID NO: 2 or 4, more preferably at least about 80%, even more preferably at least about 90-95%, and most preferably at least about 99 or 99.5% sequence identity. Further, those of the protein family encoded by LBFL303 gene, will have an amino acid sequence having at least about 50%, 60%, 70% or 75% amino acid sequence identity with the sequence set forth in SEQ ID NO: 6, 8 or 10, more preferably at least about 80-90%, even more preferably at least about 91- 94%, and most preferably at least about 95% or 98% sequence identity. Identity or homology with respect to such sequences is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with SEQ ID NO: 2, 4, 6, 8 or 10, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity (see section B for the relevant parameters). Fusion proteins, or N-terminal, C-terminal or internal extensions, deletions, or insertions into the peptide sequence shall not be construed as affecting homology.

Thus, the proteins of the present invention include molecules having the amino acid sequence disclosed in SEQ ID NO: 2, 4, 6, 8 or 10; fragments thereof having a consecutive sequence of at least about 3, 4, 5, 6, 10, 15, 20, 25, 30, 35 or more amino acid residues of these proteins; amino acid sequence variants wherein one or more amino acid residues has been inserted N- or C-terminal to, or within, the disclosed coding sequence; and amino acid sequence variants of the disclosed sequence, or their fragments



as defined above, that have been substituted by at least one residue. Such fragments, also referred to as peptides or polypeptides, may contain antigenic regions, functional regions of the protein identified as regions of the amino acid sequence which correspond to known protein domains, as well as regions of pronounced hydrophilicity. The regions  
5 are all easily identifiable by using commonly available protein sequence analysis software such as MacVector (Oxford Molecular).

Contemplated variants further include those containing predetermined mutations by, *e.g.*, homologous recombination, site-directed or PCR mutagenesis, and the corresponding proteins of other animal species, including but not limited to rabbit,  
10 mouse, rat, porcine, bovine, ovine, equine and non-human primate species, and the alleles or other naturally occurring variants of the family of proteins; and derivatives wherein the protein has been covalently modified by substitution, chemical, enzymatic, or other appropriate means with a moiety other than a naturally occurring amino acid (for example a detectable moiety such as an enzyme or radioisotope).

15 The present invention further provides compositions comprising a protein or polypeptide of the invention and a diluent. Suitable diluents can be aqueous or non-aqueous solvents or a combination thereof, and can comprise additional components, for example water-soluble salts or glycerol, that contribute to the stability, solubility, activity, and/or storage of the protein or polypeptide.

20 As described below, members of the family of proteins can be used: (1) to identify agents which modulate the level of or at least one activity of the protein, (2) to identify binding partners for the protein, (3) as an antigen to raise polyclonal or monoclonal antibodies, (4) as a therapeutic agent or target and (5) as a diagnostic agent or marker of liver cancer and other hyperplastic diseases.

25

## **B. Nucleic Acid Molecules**

The present invention further provides nucleic acid molecules that encode the protein having SEQ ID NO: 2, 4, 6, 8 or 10 and the related proteins herein described, preferably in isolated form. As used herein, "nucleic acid" is defined as RNA or DNA  
30 that encodes a protein or peptide as defined above, is complementary to a nucleic acid

sequence encoding such peptides; hybridizes to the nucleic acid of SEQ ID NO: 1, 3, 5, 7 or 9 and remains stably bound to it under appropriate stringency conditions; encodes a polypeptide sharing at least about 50%, 60%, 70% or 75%, preferably at least about 80%, more preferably at least about 85%, and most preferably at least about 90%, 95%, 98%, 99%, 99.5% or more identity with the peptide sequence of SEQ ID NO: 2 or 4, or a polypeptide sharing at least about 50%, 60%, 70% or 75%, preferably at least about 80-90%, more preferably at least about 91-92%, and most preferably at least about 93%, 95%, 98%, 99% or more identity with the peptide sequence of SEQ ID NO: 6 or 8; or exhibits at least 50%, 60%, 70% or 75%, preferably at least about 80%, more preferably at least about 85%, and even more preferably at least about 90%, 95%, 98%, 99%, 99.5% or more nucleotide sequence identity over the open reading frames of SEQ ID NO: 1 or 3, or at least 50%, 60%, 70% or 75%, preferably at least about 80-90%, more preferably at least about 91-92%, and even more preferably at least about 93%, 95%, 98%, 99% or more nucleotide sequence identity over the open reading frames of SEQ ID NO: 5, 7 or 9.

The present invention further includes isolated nucleic acid molecules that specifically hybridize to the complement of SEQ ID NO: 1, 3, 5, 7 or 9, particularly molecules that specifically hybridize over the open reading frames. Such molecules that specifically hybridize to the complement of SEQ ID NO: 1, 3, 5, 7 or 9 typically do so under stringent hybridization conditions.

Specifically contemplated are genomic DNA, cDNA, mRNA and antisense molecules, as well as nucleic acids based on alternative backbones or including alternative bases, whether derived from natural sources or synthesized. Such hybridizing or complementary nucleic acids, however, are defined further as being novel and unobvious over any prior art nucleic acid including that which encodes, hybridizes under appropriate stringency conditions, or is complementary to nucleic acid encoding a protein according to the present invention.

Homology or identity at the nucleotide or amino acid sequence level is determined by BLAST (Basic Local Alignment Search Tool) analysis using the algorithm employed by the programs *blastp*, *blastn*, *blastx*, *tblastn* and *tblastx* (Altschul *et al.*, (1997) *Nucleic Acids Res* 25:3389-3402, and Karlin *et al.*, (1990) *Proc*

*Natl Acad Sci USA* 87:2264-2268, both fully incorporated by reference) which are tailored for sequence similarity searching. The approach used by the **BLAST** program is to first consider similar segments, with and without gaps, between a query sequence and a database sequence, then to evaluate the statistical significance of all matches that are identified and finally to summarize only those matches which satisfy a preselected threshold of significance. For a discussion of basic issues in similarity searching of sequence databases, see Altschul *et al.*, (1994) *Nature Genetics* 6: 119-129 which is fully incorporated by reference. The search parameters for **histogram**, **descriptions**, **alignments**, **expect** (*i.e.*, the statistical significance threshold for reporting matches against database sequences), **cutoff**, **matrix** and **filter** (low complexity) are at the default settings. The default scoring matrix used by **blastp**, **blastx**, **tblastn**, and **tblastx** is the **BLOSUM62** matrix (Henikoff *et al.*, (1992) *Proc Natl Acad Sci USA* 89:10915-10919, fully incorporated by reference), recommended for query sequences over 85 nucleotides or amino acids in length.

For **blastn**, the scoring matrix is set by the ratios of **M** (*i.e.*, the reward score for a pair of matching residues) to **N** (*i.e.*, the penalty score for mismatching residues), wherein the default values for **M** and **N** are 5 and -4, respectively. Four **blastn** parameters were adjusted as follows: **Q**=10 (gap creation penalty); **R**=10 (gap extension penalty); **wink**=1 (generates word hits at every **wink**<sup>th</sup> position along the query); and **gapw**=16 (sets the window width within which gapped alignments are generated). The equivalent **Blastp** parameter settings were **Q**=9; **R**=2; **wink**=1; and **gapw**=32. A **Bestfit** comparison between sequences, available in the GCG package version 10.0, uses DNA parameters **GAP**=50 (gap creation penalty) and **LEN**=3 (gap extension penalty) and the equivalent settings in protein comparisons are **GAP**=8 and **LEN**=2.

"Stringent conditions" are those that (1) employ low ionic strength and high temperature for washing, for example, 0.015 M NaCl/0.0015 M sodium citrate/0.1% SDS at 50 °C, or (2) employ during hybridization a denaturing agent such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42 °C. Another example is hybridization in 50%

formamide, 5× SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5× Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42 °C, with washes at 42 °C in 0.2× SSC and 0.1% SDS. A skilled artisan can readily determine and vary the stringency conditions appropriately to obtain a clear and detectable hybridization signal. Preferred molecules are those that hybridize under the above conditions to the complement of SEQ ID NO: 1, 3, 5 or 7 and which encode a functional or full-length protein. Even more preferred hybridizing molecules are those that hybridize under the above conditions to the complement strand of the open reading frame of SEQ ID NO: 1, 3, 5, 7 or 9.

As used herein, a nucleic acid molecule is said to be "isolated" when the nucleic acid molecule is substantially separated from contaminant nucleic acid molecules encoding other polypeptides.

The present invention further provides fragments of the disclosed nucleic acid molecules. As used herein, a fragment of a nucleic acid molecule refers to a small portion of the coding or non-coding sequence. The size of the fragment will be determined by the intended use. For example, if the fragment is chosen so as to encode an active portion of the protein, the fragment will need to be large enough to encode the functional region(s) of the protein. For instance, fragments which encode peptides corresponding to predicted antigenic regions may be prepared. If the fragment is to be used as a nucleic acid probe or PCR primer, then the fragment length is chosen so as to obtain a relatively small number of false positives during probing/priming (see the discussion in Section H).

Fragments of the nucleic acid molecules of the present invention (*i.e.*, synthetic oligonucleotides) that are used as probes or specific primers for the polymerase chain reaction (PCR), or to synthesize gene sequences encoding proteins of the invention, can easily be synthesized by chemical techniques, for example, the phosphoramidite method of Matteucci *et al.*, ((1981) *J Am Chem Soc* 103:3185-3191) or using automated synthesis methods. In addition, larger DNA segments can readily be prepared by well known methods, such as synthesis of a group of oligonucleotides that define various

modular segments of the gene, followed by ligation of oligonucleotides to build the complete modified gene.

The nucleic acid molecules of the present invention may further be modified so as to contain a detectable label for diagnostic and probe purposes. A variety of such labels are known in the art and can readily be employed with the encoding molecules herein described. Suitable labels include, but are not limited to, biotin, radiolabeled or fluorescently labeled nucleotides and the like. A skilled artisan can readily employ any such label to obtain labeled variants of the nucleic acid molecules of the invention.

#### C. Isolation of Other Related Nucleic Acid Molecules

As described above, the identification and characterization of the nucleic acid molecule having SEQ ID NO: 1, 3, 5, 7 or 9 allows a skilled artisan to isolate nucleic acid molecules that encode other members of the protein family in addition to the sequences herein described. Further, the presently disclosed nucleic acid molecules allow a skilled artisan to isolate nucleic acid molecules that encode other members of the family of proteins in addition to the proteins having SEQ ID NO: 2, 4, 6, 8 or 10.

For instance, a skilled artisan can readily use the amino acid sequence of SEQ ID NO: 2, 4, 6, 8 or 10 to generate antibody probes to screen expression libraries prepared from appropriate cells. Typically, polyclonal antiserum from mammals such as rabbits immunized with the purified protein (as described below) or monoclonal antibodies can be used to probe a mammalian cDNA or genomic expression library, such as lambda gt11 library, to obtain the appropriate coding sequence for other members of the protein family. The cloned cDNA sequence can be expressed as a fusion protein, expressed directly using its own control sequences, or expressed by constructions using control sequences appropriate to the particular host used for expression of the enzyme.

Alternatively, a portion of the coding sequence herein described can be synthesized and used as a probe to retrieve DNA encoding a member of the protein family from any mammalian organism. Oligomers containing approximately 18-20 nucleotides (encoding about a 6-7 amino acid stretch) are prepared and used to screen genomic DNA or cDNA libraries to obtain hybridization under stringent conditions or

conditions of sufficient stringency to eliminate an undue level of false positives.

Additionally, pairs of oligonucleotide primers can be prepared for use in a polymerase chain reaction (PCR) to selectively clone an encoding nucleic acid molecule. A PCR denature/anneal/extend cycle for using such PCR primers is well known in the art and can readily be adapted for use in isolating other encoding nucleic acid molecules.

Nucleic acid molecules encoding other members of the protein family may also be identified in existing genomic or other sequence information using any available computational method, including but not limited to: PSI-BLAST (Altschul *et al.*, (1997) *Nucleic Acids Res* 25:3389-3402); PHI-BLAST (Zhang *et al.*, (1998) *Nucleic Acids Res* 26:3986-3990), 3D-PSSM (Kelly *et al.*, (2000) *J Mol Biol* 299(2):499-520); and other computational analysis methods (Shi *et al.*, (1999) *Biochem Biophys Res Commun* 262(1):132-138 and Matsunami *et. al.*, (2000) *Nature* 404(6778):601-604.

#### D. rDNA molecules Containing a Nucleic Acid Molecule

The present invention further provides recombinant DNA molecules (rDNAs) that contain a coding sequence. As used herein, a rDNA molecule is a DNA molecule that has been subjected to molecular manipulation *in situ*. Methods for generating rDNA molecules are well known in the art, for example, see Sambrook *et al.*, Molecular Cloning - A Laboratory Manual, Third Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001. In the preferred rDNA molecules, a coding DNA sequence is operably linked to expression control sequences and/or vector sequences.

The choice of vector and/or expression control sequences to which one of the protein family encoding sequences of the present invention is operably linked depends directly, as is well known in the art, on the functional properties desired, *e.g.*, protein expression, and the host cell to be transformed. A vector contemplated by the present invention is at least capable of directing the replication or insertion into the host chromosome, and preferably also expression, of the structural gene included in the rDNA molecule.

Expression control elements that are used for regulating the expression of an operably linked protein encoding sequence are known in the art and include, but are not

limited to, inducible promoters, constitutive promoters, secretion signals, and other regulatory elements. Preferably, the inducible promoter is readily controlled, such as being responsive to a nutrient in the host cell's medium.

In one embodiment, the vector containing a coding nucleic acid molecule will include a prokaryotic replicon, *i.e.*, a DNA sequence having the ability to direct autonomous replication and maintenance of the recombinant DNA molecule extrachromosomally in a prokaryotic host cell, such as a bacterial host cell, transformed therewith. Such replicons are well known in the art. In addition, vectors that include a prokaryotic replicon may also include a gene whose expression confers a detectable marker such as a drug resistance. Typical bacterial drug resistance genes are those that confer resistance to ampicillin, kanamycin, chloramphenicol or tetracycline.

Vectors that include a prokaryotic replicon can further include a prokaryotic or bacteriophage promoter capable of directing the expression (transcription and translation) of the coding gene sequences in a bacterial host cell, such as *E. coli*. A promoter is an expression control element formed by a DNA sequence that permits binding of RNA polymerase and transcription to occur. Promoter sequences compatible with bacterial hosts are typically provided in plasmid vectors containing convenient restriction sites for insertion of a DNA segment of the present invention. Typical of such vector plasmids are pUC8, pUC9, pBR322 and pBR329 available from BioRad Laboratories, (Richmond, CA), pPL and pKK223 available from Pharmacia (Piscataway, NJ).

Expression vectors compatible with eukaryotic cells, preferably those compatible with vertebrate cells, such as liver cells, can also be used to form rDNA molecules that contain a coding sequence. Eukaryotic cell expression vectors, including viral vectors, are well known in the art and are available from several commercial sources. Typically, such vectors are provided containing convenient restriction sites for insertion of the desired DNA segment. Typical of such vectors are pSVL and pKSV-10 (Pharmacia), pBPV-1/pML2d (International Biotechnologies, Inc.), pTDT1 (ATCC, #31255), the vector pCDM8 described herein, and the like eukaryotic expression vectors. Vectors may be modified to include liver cell specific promoters if

needed.

Eukaryotic cell expression vectors used to construct the rDNA molecules of the present invention may further include a selectable marker that is effective in an eukaryotic cell, preferably a drug resistance selection marker. A preferred drug resistance marker is the gene whose expression results in neomycin resistance, *i.e.*, the neomycin phosphotransferase (*neo*) gene. (Southern *et al.*, (1982) *J Mol Anal Genet* 1:327-341) Alternatively, the selectable marker can be present on a separate plasmid, and the two vectors are introduced by co-transfection of the host cell, and selected by culturing in the appropriate drug for the selectable marker.

#### **E. Host Cells Containing an Exogenously Supplied Coding Nucleic Acid Molecule**

The present invention further provides host cells transformed with a nucleic acid molecule that encodes a protein of the present invention. The host cell can be either prokaryotic or eukaryotic. Eukaryotic cells useful for expression of a protein of the invention are not limited, so long as the cell line is compatible with cell culture methods and compatible with the propagation of the expression vector and expression of the gene product. Preferred eukaryotic host cells include, but are not limited to, yeast, insect and mammalian cells, preferably vertebrate cells such as those from a mouse, rat, monkey or human cell line. Preferred eukaryotic host cells include Chinese hamster ovary (CHO) cells available from the ATCC as CCL61, NIH Swiss mouse embryo cells (NIH/3T3) available from the ATCC as CRL 1658, baby hamster kidney cells (BHK), and the like eukaryotic tissue culture cell lines.

Any prokaryotic host can be used to express a rDNA molecule encoding a protein of the invention. The preferred prokaryotic host is *E. coli*.

Transformation of appropriate cell hosts with a rDNA molecule of the present invention is accomplished by well known methods that typically depend on the type of vector used and host system employed. With regard to transformation of prokaryotic host cells, electroporation and salt treatment methods are typically employed (see, for example, Cohen *et al.*, (1972) *Proc Natl Acad Sci USA* 69:2110; and Sambrook *et al.*, *supra*). With regard to transformation of vertebrate cells with vectors containing



rDNAs, electroporation, cationic lipid or salt treatment methods are typically employed, see, for example, Graham *et al.*, (1973) *Virol* 52:456; Wigler *et al.*, (1979) *Proc Natl Acad Sci USA* 76:1373-1376.

Successfully transformed cells, *i.e.*, cells that contain a rDNA molecule of the present invention, can be identified by well known techniques including the selection for a selectable marker. For example, cells resulting from the introduction of an rDNA of the present invention can be cloned to produce single colonies. Cells from those colonies can be harvested, lysed and their DNA content examined for the presence of the rDNA using a method such as that described by Southern, (1975) *J Mol Biol* 98:503 or Berent *et al.*, (1985) *Biotech* 3:208, or the proteins produced from the cell assayed via an immunological method.

#### F. Production of Recombinant Proteins using a rDNA Molecule

The present invention further provides methods for producing a protein of the invention using nucleic acid molecules herein described. In general terms, the production of a recombinant form of a protein typically involves the following steps:

First, a nucleic acid molecule is obtained that encodes a protein of the invention, such as a nucleic acid molecule comprising, consisting essentially of or consisting of SEQ ID NO: 1 or SEQ ID NO: 3; nucleotides 155-421 or 155-418 of SEQ ID NO: 1; nucleotides 139-405 or 139-402 of SEQ ID NO: 3; SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9; nucleotides 32-1387 or 32-1384 of SEQ ID NO: 5; nucleotides 41-1504 or 41-1501 of SEQ ID NO: 7; or nucleotides 31-1554 or 31-1551 of SEQ ID NO: 9. If the encoding sequence is uninterrupted by introns, as are these open-reading-frames, it is directly suitable for expression in any host.

The nucleic acid molecule is then preferably placed in operable linkage with suitable control sequences, as described above, to form an expression unit containing the protein open reading frame. The expression unit is used to transform a suitable host and the transformed host is cultured under conditions that allow the production of the recombinant protein. Optionally the recombinant protein is isolated from the medium or from the cells; recovery and purification of the protein may not be necessary in some

instances where some impurities may be tolerated.

Each of the foregoing steps can be done in a variety of ways. For example, the desired coding sequences may be obtained from genomic fragments and used directly in appropriate hosts. The construction of expression vectors that are operable in a variety of hosts is accomplished using appropriate replicons and control sequences, as set forth above. The control sequences, expression vectors, and transformation methods are dependent on the type of host cell used to express the gene and were discussed in detail earlier. Suitable restriction sites can, if not normally available, be added to the ends of the coding sequence so as to provide an excisable gene to insert into these vectors. A skilled artisan can readily adapt any host/expression system known in the art for use with the nucleic acid molecules of the invention to produce recombinant protein.

#### G. Methods to Identify Binding Partners

Another embodiment of the present invention provides methods for isolating and identifying binding partners of proteins of the invention. In general, a protein of the invention is mixed with a potential binding partner or an extract or fraction of a cell under conditions that allow the association of potential binding partners with the protein of the invention. After mixing, peptides, polypeptides, proteins or other molecules that have become associated with a protein of the invention are separated from the mixture. The binding partner that bound to the protein of the invention can then be removed and further analyzed. To identify and isolate a binding partner, the entire protein, for instance a protein comprising the entire amino acid sequence of SEQ ID NO: 2, 4, 6, 8 or 10 can be used. Alternatively, a fragment of the protein can be used.

As used herein, a cellular extract refers to a preparation or fraction which is made from a lysed or disrupted cell. The preferred source of cellular extracts will be cells derived from human liver tumors or transformed liver cells, for instance, biopsy tissue or tissue culture cells from hepatic carcinomas. Alternatively, cellular extracts may be prepared from normal tissue or available cell lines, particularly liver-derived cell lines.

A variety of methods can be used to obtain an extract of a cell. Cells can be

disrupted using either physical or chemical disruption methods. Examples of physical disruption methods include, but are not limited to, sonication and mechanical shearing. Examples of chemical lysis methods include, but are not limited to, detergent lysis and enzyme lysis. A skilled artisan can readily adapt methods for preparing cellular  
5 extracts in order to obtain extracts for use in the present methods.

Once an extract of a cell is prepared, the extract is mixed with the protein of the invention under conditions in which association of the protein with the binding partner can occur. A variety of conditions can be used, the most preferred being conditions that closely resemble conditions found in the cytoplasm of a human cell. Features such as  
10 osmolarity, pH, temperature, and the concentration of cellular extract used, can be varied to optimize the association of the protein with the binding partner.

After mixing under appropriate conditions, the bound complex is separated from the mixture. A variety of techniques can be utilized to separate the mixture. For example, antibodies specific to a protein of the invention can be used to  
15 immunoprecipitate the binding partner complex. Alternatively, standard chemical separation techniques such as chromatography and density/sediment centrifugation can be used.

After removal of non-associated cellular constituents found in the extract, the binding partner can be dissociated from the complex using conventional methods. For  
20 example, dissociation can be accomplished by altering the salt concentration or pH of the mixture.

To aid in separating associated binding partner pairs from the mixed extract, the protein of the invention can be immobilized on a solid support. For example, the protein can be attached to a nitrocellulose matrix or acrylic beads. Attachment of the  
25 protein to a solid support aids in separating peptide/binding partner pairs from other constituents found in the extract. The identified binding partners can be either a single protein or a complex made up of two or more proteins. Alternatively, binding partners may be identified using a Far-Western assay according to the procedures of Takayama *et al.*, (1997) *Methods Mol Biol* 69:171-184 or Sauder *et al.*, (1996) *J Gen Virol* 77:991-996  
30 or identified through the use of epitope tagged proteins or GST fusion proteins.

Alternatively, the nucleic acid molecules of the invention can be used in a yeast two-hybrid system or other *in vivo* protein-protein detection system. The yeast two-hybrid system has been used to identify other protein partner pairs and can readily be adapted to employ the nucleic acid molecules herein described.

5

#### **H. Methods to Identify Agents that Modulate the Expression a Nucleic Acid Encoding the Genes Associated with Liver Cancer**

Another embodiment of the present invention provides methods for identifying agents that modulate the expression of a nucleic acid encoding a protein of the invention such as a protein having the amino acid sequence of SEQ ID NO: 2, 4, 6, 8 or 10. Such assays may utilize any available means of monitoring for changes in the expression level of the nucleic acids of the invention. As used herein, an agent is said to modulate the expression of a nucleic acid of the invention if it is capable of up- or down-regulating expression of the nucleic acid in a cell.

15 In one assay format, cell lines that contain reporter gene fusions between nucleotides from within the open reading frame defined by nucleotides 155-421 of SEQ ID NO: 1, nucleotides 139-405 of SEQ ID NO: 3, nucleotides 32-1387 of SEQ ID NO: 5, nucleotides 41-1504 of SEQ ID NO: 7, or nucleotides 31-1554 of SEQ ID NO: 9 and/or the 5' and/or 3' regulatory elements and any assayable fusion partner may be prepared. Numerous assayable fusion partners are known and readily available including the firefly luciferase gene and the gene encoding chloramphenicol acetyltransferase (Alam *et al.*, (1990) *Anal Biochem* 188:245-254). Cell lines containing the reporter gene fusions are then exposed to the agent to be tested under appropriate conditions and time. Differential expression of the reporter gene between samples exposed to the agent and control samples identifies agents which modulate the expression of a nucleic acid of the invention.

25 Additional assay formats may be used to monitor the ability of the agent to modulate the expression of a nucleic acid encoding a protein of the invention, such as the protein having SEQ ID NO: 2, 4, 6, 8 or 10. For instance, mRNA expression may be monitored directly by hybridization to the nucleic acids of the invention. Cell lines are

30

exposed to the agent to be tested under appropriate conditions and time and total RNA or mRNA is isolated by standard procedures such those disclosed in Sambrook *et al.*, Molecular Cloning - A Laboratory Manual, Third Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001.

5           The preferred cells will be those derived from human liver tissue, for instance, liver biopsy tissue or cultured cells from patients with liver cancer, or liver cancer and cirrhosis, or liver cancer and hepatitis. Cell lines such as ATCC hepatocellular carcinoma cell lines Catalogue Nos. HB-8064, HB-8065 or CRL-10741 may be used. Alternatively, other available cells or cell lines may be used.

10           Probes to detect differences in RNA expression levels between cells exposed to the agent and control cells may be prepared from the nucleic acids of the invention. It is preferable, but not necessary, to design probes which hybridize only with target nucleic acids under conditions of high stringency. Only highly complementary nucleic acid hybrids form under conditions of high stringency. Accordingly, the stringency of  
15 the assay conditions determines the amount of complementarity which should exist between two nucleic acid strands in order to form a hybrid. Stringency should be chosen to maximize the difference in stability between the probe:target hybrid and probe:non-target hybrids.

20           Probes may be designed from the nucleic acids of the invention through methods known in the art. For instance, the G+C content of the probe and the probe length can affect probe binding to its target sequence. Methods to optimize probe specificity are commonly available in Sambrook *et al.*, *supra*, or Ausubel *et al.*, Short Protocols in Molecular Biology, Fourth Ed., John Wiley & Sons, Inc., New York, 1999.

25           Hybridization conditions are modified using known methods, such as those described by Sambrook *et al.* and Ausubel *et al.* as required for each probe. Hybridization of total cellular RNA or RNA enriched for polyA RNA can be accomplished in any available format. For instance, total cellular RNA or RNA enriched for polyA RNA can be affixed to a solid support and the solid support exposed to at least one probe comprising at least one, or part of one of the sequences of the  
30 invention under conditions in which the probe will specifically hybridize. Alternatively,

nucleic acid fragments comprising at least one, or part of one of the sequences of the invention can be affixed to a solid support, such as a silicon chip, porous glass wafer or membrane. The solid support can then be exposed to total cellular RNA or polyA RNA from a sample under conditions in which the affixed sequences will specifically  
5 hybridize. Such solid supports and hybridization methods are widely available, for example, those disclosed by Beattie, (1995) WO 95/11755. By examining for the ability of a given probe to specifically hybridize to an RNA sample from an untreated cell population and from a cell population exposed to the agent, agents which up- or down-regulate the expression of a nucleic acid encoding the protein having the sequence  
10 of SEQ ID NO: 2, 4, 6, 8 or 10 are identified.

Hybridization for qualitative and quantitative analysis of mRNAs may also be carried out by using a RNase Protection Assay (*i.e.*, RPA, see Ma *et al.*, (1996) *Methods* 10:273-238). Briefly, an expression vehicle comprising cDNA encoding the gene product and a phage specific DNA dependent RNA polymerase promoter (*e.g.*, T7, T3  
15 or SP6 RNA polymerase) is linearized at the 3' end of the cDNA molecule, downstream from the phage promoter, wherein such a linearized molecule is subsequently used as a template for synthesis of a labeled antisense transcript of the cDNA by *in vitro* transcription. The labeled transcript is then hybridized to a mixture of isolated RNA (*i.e.*, total or fractionated mRNA) by incubation at 45 °C overnight in a buffer comprising  
20 80% formamide, 40 mM Pipes, pH 6.4, 0.4 M NaCl and 1 mM EDTA. The resulting hybrids are then digested in a buffer comprising 40 µg/ml ribonuclease A and 2 µg/ml ribonuclease. After deactivation and extraction of extraneous proteins, the samples are loaded onto urea/polyacrylamide gels for analysis.

In another assay, to identify agents which affect the expression of the instant  
25 gene products, cells or cell lines are first identified which express the gene products of the invention physiologically. Cell and/or cell lines so identified would be expected to comprise the necessary cellular machinery such that the fidelity of modulation of the transcriptional apparatus is maintained with regard to exogenous contact of agent with appropriate surface transduction mechanisms and/or the cytosolic cascades. Further,  
30 such cells or cell lines would be transduced or transfected with an expression vehicle

(e.g., a plasmid or viral vector) construct comprising an operable non-translated 5'promoter-containing end of the structural gene encoding the instant gene products fused to one or more antigenic fragments, which are peculiar to the instant gene products, wherein said fragments are under the transcriptional control of said promoter and are expressed as polypeptides whose molecular weight can be distinguished from the naturally occurring polypeptides or may further comprise an immunologically distinct tag or other detectable marker. Such a process is well known in the art (see Sambrook *et al.*, *supra*).

Cells or cell lines transduced or transfected as outlined above are then contacted with agents under appropriate conditions. For example, the agent in a pharmaceutically acceptable excipient is contacted with cells in an aqueous physiological buffer such as phosphate buffered saline (PBS) at physiological pH, Eagles balanced salt solution (BSS) at physiological pH, PBS or BSS comprising serum or conditioned media comprising PBS or BSS and/or serum incubated at 37 °C. Said conditions may be modulated as deemed necessary by one of skill in the art. Subsequent to contacting the cells with the agent, said cells will be disrupted and the polypeptides of the lysate are fractionated such that a polypeptide fraction is pooled and contacted with an antibody to be further processed by immunological assay (e.g., ELISA, immunoprecipitation or Western blot). The pool of proteins isolated from the "agent-contacted" sample will be compared with a control sample where only the excipient is contacted with the cells and an increase or decrease in the immunologically generated signal from the "agent-contacted" sample compared to the control will be used to distinguish the effectiveness of the agent.

#### **H. Methods to Identify Agents that Modulate the Level or at Least One Activity of the Liver Cancer Associated Proteins**

Another embodiment of the present invention provides methods for identifying agents that modulate the level or at least one activity of a protein of the invention such as the protein having the amino acid sequence of SEQ ID NO: 2, 4, 6, 8 or 10. Such methods or assays may utilize any means of monitoring or detecting the desired activity.

In one format, the relative amounts of a protein of the invention between a cell

population that has been exposed to the agent to be tested compared to an un-exposed control cell population may be assayed. In this format, probes such as specific antibodies are used to monitor the differential expression of the protein in the different cell populations. Cell lines or populations are exposed to the agent to be tested under appropriate conditions and time. Cellular lysates may be prepared from the exposed cell line or population and a control, unexposed cell line or population. The cellular lysates are then analyzed with the probe.

Antibody probes are prepared by immunizing suitable mammalian hosts in appropriate immunization protocols using the peptides, polypeptides or proteins of the invention if they are of sufficient length, or, if desired, or if required to enhance immunogenicity, conjugated to suitable carriers. Methods for preparing immunogenic conjugates with carriers such as BSA, KLH, or other carrier proteins are well known in the art. In some circumstances, direct conjugation using, for example, carbodiimide reagents may be effective; in other instances linking reagents such as those supplied by Pierce Chemical Co. (Rockford, IL), may be desirable to provide accessibility to the hapten. The hapten peptides can be extended at either the amino or carboxy terminus with a cysteine residue or interspersed with cysteine residues, for example, to facilitate linking to a carrier. Administration of the immunogens is conducted generally by injection over a suitable time period and with use of suitable adjuvants, as is generally understood in the art. During the immunization schedule, titers of antibodies are taken to determine adequacy of antibody formation.

While the polyclonal antisera produced in this way may be satisfactory for some applications, for pharmaceutical compositions, use of monoclonal preparations is preferred. Immortalized cell lines which secrete the desired monoclonal antibodies may be prepared using the standard method of Kohler and Milstein ((1975) *Nature* 256:495-497) or modifications which effect immortalization of lymphocytes or spleen cells, as is generally known. The immortalized cell lines secreting the desired antibodies are screened by immunoassay in which the antigen is the peptide hapten, polypeptide or protein. When the appropriate immortalized cell culture secreting the desired antibody is identified, the cells can be cultured either *in vitro* or by production in



ascites fluid.

The desired monoclonal antibodies are then recovered from the culture supernatant or from the ascites supernatant. Fragments of the monoclonal antibodies or the polyclonal antisera which contain the immunologically significant (antigen-binding) portion can be used as antagonists, as well as the intact antibodies. Use of immunologically reactive (antigen-binding) antibody fragments, such as the Fab, Fab', or F(ab')<sub>2</sub> fragments is often preferable, especially in a therapeutic context, as these fragments are generally less immunogenic than the whole immunoglobulin.

The antibodies or antigen-binding fragments may also be produced, using current technology, by recombinant means. Antibody regions that bind specifically to the desired regions of the protein can also be produced in the context of chimeras with multiple species origin, such as humanized antibodies.

Agents that are assayed in the above method can be randomly selected or rationally selected or designed. As used herein, an agent is said to be randomly selected when the agent is chosen randomly without considering the specific sequences involved in the association of a protein of the invention alone or with its associated substrates, binding partners, etc. An example of randomly selected agents is the use a chemical library or a peptide combinatorial library, or a growth broth of an organism.

As used herein, an agent is said to be rationally selected or designed when the agent is chosen on a nonrandom basis which takes into account the sequence of the target site and/or its conformation in connection with the agent's action. Agents can be rationally selected or rationally designed by utilizing the peptide sequences that make up these sites. For example, a rationally selected peptide agent can be a peptide whose amino acid sequence is identical to or a derivative of any functional consensus site.

The agents of the present invention can be, as examples, peptides, small molecules, vitamin derivatives, as well as carbohydrates. Dominant negative proteins, DNAs encoding these proteins, antibodies to these proteins, peptide fragments of these proteins or mimics of these proteins may be introduced into cells to affect function. "Mimic" used herein refers to the modification of a region or several regions of a peptide molecule to provide a structure chemically different from the parent peptide but

topographically and functionally similar to the parent peptide (see Grant in: Molecular Biology and Biotechnology, Meyers, ed., pp. 659-664, VCH Publishers, Inc., New York, 1995). A skilled artisan can readily recognize that there is no limit as to the structural nature of the agents of the present invention.

5       The peptide agents of the invention can be prepared using standard solid phase (or solution phase) peptide synthesis methods, as is known in the art. In addition, the DNA encoding these peptides may be synthesized using commercially available oligonucleotide synthesis instrumentation and produced recombinantly using standard recombinant production systems. The production using solid phase peptide synthesis is  
10       necessitated if non-gene-encoded amino acids are to be included.

Another class of agents of the present invention are antibodies immunoreactive with critical positions of proteins of the invention. Antibody agents are obtained by immunization of suitable mammalian subjects with peptides, containing as antigenic regions, those portions of the protein intended to be targeted by the antibodies.

15  
**J. Uses for Agents that Modulate the Expression or at Least one Activity of the Proteins Associated with Liver Cancer**

As provided in the Examples, the proteins and nucleic acids of the invention, such as the proteins having the amino acid sequence of SEQ ID NO: 2, 4, 6, 8 or 10, are  
20       differentially expressed in cancerous liver tissue. Agents that up- or down- regulate or modulate the expression of the protein or at least one activity of the protein, such as agonists or antagonists, of may be used to modulate biological and pathologic processes associated with the protein's function and activity.

As used herein, a subject can be any mammal, so long as the mammal is in need  
25       of modulation of a pathological or biological process mediated by a protein of the invention. The term "mammal" is defined as an individual belonging to the class Mammalia. The invention is particularly useful in the treatment of human subjects.

Pathological processes refer to a category of biological processes which produce a deleterious effect. For example, expression of a protein of the invention may be  
30       associated with liver cell growth or hyperplasia. As used herein, an agent is said to

modulate a pathological process when the agent reduces the degree or severity of the process. For instance, liver cancer may be prevented or disease progression modulated by the administration of agents which up- or down-regulate or modulate in some way the expression or at least one activity of a protein of the invention.

5           The agents of the present invention can be provided alone, or in combination with other agents that modulate a particular pathological process. For example, an agent of the present invention can be administered in combination with other known drugs. As used herein, two agents are said to be administered in combination when the two agents are administered simultaneously or are administered independently in a  
10   fashion such that the agents will act at the same time.

          The agents of the present invention can be administered via parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, or buccal routes. Alternatively, or concurrently, administration may be by the oral route. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of  
15   concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.

          The present invention further provides compositions containing one or more agents which modulate expression or at least one activity of a protein of the invention. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art. Typical dosages comprise 0.1 to 100  
20    $\mu\text{g/kg}$  body wt. The preferred dosages comprise 0.1 to 10  $\mu\text{g/kg}$  body wt. The most preferred dosages comprise 0.1 to 1  $\mu\text{g/kg}$  body wt.

          In addition to the pharmacologically active agent, the compositions of the present invention may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into  
25   preparations which can be used pharmaceutically for delivery to the site of action. Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example,  
30   sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides.

Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers. Liposomes can also be used to encapsulate the agent for delivery into the cell.

5 The pharmaceutical formulation for systemic administration according to the invention may be formulated for enteral, parenteral or topical administration. Indeed, all three types of formulations may be used simultaneously to achieve systemic administration of the active ingredient.

Suitable formulations for oral administration include hard or soft gelatin capsules, pills, tablets, including coated tablets, elixirs, suspensions, syrups or  
10 inhalations and controlled release forms thereof.

In practicing the methods of this invention, the compounds of this invention may be used alone or in combination, or in combination with other therapeutic or diagnostic agents. In certain preferred embodiments, the compounds of this invention  
15 may be coadministered along with other compounds typically prescribed for these conditions according to generally accepted medical practice. The compounds of this invention can be utilized *in vivo*, ordinarily in mammals, such as humans, sheep, horses, cattle, pigs, dogs, cats, rats and mice, or *in vitro*.

## 20 K. Transgenic Animals

Transgenic animals containing mutant, knock-out or modified genes corresponding to the cDNA sequence of SEQ ID NO: 1, 3, 5, 7 or 9, or the open reading frame encoding the polypeptide sequence of SEQ ID NO: 2, 4, 6, 8 or 10 or fragments thereof having a consecutive sequence of at least about 3, 4, 5, 6, 10, 15, 20, 25, 30, 35  
25 or more amino acid residues, are also included in the invention. Transgenic animals are genetically modified animals into which recombinant, exogenous or cloned genetic material has been experimentally transferred. Such genetic material is often referred to as a "transgene." The nucleic acid sequence of the transgene, in this case a form of SEQ ID NO: 1, 3, 5, 7 or 9, may be integrated either at a locus of a genome where that  
30 particular nucleic acid sequence is not otherwise normally found or at the normal locus

for the transgene. The transgene may consist of nucleic acid sequences derived from the genome of the same species or of a different species than the species of the target animal.

In some embodiments, transgenic animals in which all or a portion of a gene comprising SEQ ID NO: 1, 3, 5, 7 or 9 is deleted may be constructed. In those cases where the gene corresponding to SEQ ID NO: 1, 3, 5, 7 or 9 contains one or more introns, the entire gene- all exons, introns and the regulatory sequences- may be deleted. Alternatively, less than the entire gene may be deleted. For example, a single exon and/or intron may be deleted, so as to create an animal expressing a modified version of a protein of the invention.

The term "germ cell line transgenic animal" refers to a transgenic animal in which the genetic alteration or genetic information was introduced into a germ line cell, thereby conferring the ability of the transgenic animal to transfer the genetic information to offspring. If such offspring in fact possess some or all of that alteration or genetic information, then they too are transgenic animals.

The alteration or genetic information may be foreign to the species of animal to which the recipient belongs, foreign only to the particular individual recipient, or may be genetic information already possessed by the recipient. In the last case, the altered or introduced gene may be expressed differently than the native gene.

Transgenic animals can be produced by a variety of different methods including transfection, electroporation, microinjection, gene targeting in embryonic stem cells and recombinant viral and retroviral infection (*see, e.g.*, U.S. Patent No. 4,736,866; U.S. Patent No. 5,602,307; Mullins *et al.*, (1993) *Hypertension* 22:630-633; Brenin *et al.*, (1997) *Surg Oncol* 6:99-110; Recombinant Gene Expression Protocols (Methods in Molecular Biology, Vol. 62), Tuan, ed., Humana Press, Totowa, NJ, 1997).

A number of recombinant or transgenic mice have been produced, including those which express an activated oncogene sequence (U.S. Patent No. 4,736,866); express simian SV40 T-antigen (U.S. Patent No. 5,728,915); lack the expression of interferon regulatory factor 1 (IRF-1) (U.S. Patent No. 5,731,490); exhibit dopaminergic dysfunction (U.S. Patent No. 5,723,719); express at least one human gene which participates in blood pressure control (U.S. Patent No. 5,731,489); display greater

similarity to the conditions existing in naturally occurring Alzheimer's disease (U.S. Patent No. 5,720,936); have a reduced capacity to mediate cellular adhesion (U.S. Patent No. 5,602,307); possess a bovine growth hormone gene (Clutter *et al.*, (1996) *Genetics* 143:1753-1760); or, are capable of generating a fully human antibody response (McCarthy (1997) *Lancet* 349:405).

While mice and rats remain the animals of choice for most transgenic experimentation, in some instances it is preferable or even necessary to use alternative animal species. Transgenic procedures have been successfully utilized in a variety of non-murine animals, including sheep, goats, pigs, dogs, cats, monkeys, chimpanzees, hamsters, rabbits, cows and guinea pigs (see, *e.g.*, Kim *et al.*, (1997) *Mol Reprod Dev* 46:515-526; Houdebine, (1995) *Reprod Nutr Dev* 35:609-617; Petters (1994) *Reprod Fertil Dev* 6:643-645; Schnieke *et al.*, (1997) *Science* 278:2130-2133; and Amoah, (1997) *J Animal Science* 75:578-585).

The method of introduction of nucleic acid fragments into recombination competent mammalian cells can be by any method which favors co-transformation of multiple nucleic acid molecules. Detailed procedures for producing transgenic animals are readily available to one skilled in the art, including the disclosures in U.S. Patent No. 5,489,743 and U.S. Patent No. 5,602,307.

## **L. Diagnostic Methods**

As the genes and proteins of the invention are differentially expressed in cancerous liver tissue (HCC) and in other carcinomas, compared to non-cancerous tissues, the genes and proteins of the invention may be used to diagnose or monitor liver cancer or other malignant neoplasms, to track disease progression, or to differentiate HCC tissue from cirrhotic tissue samples. One means of diagnosing liver cancer using the nucleic acid molecules or proteins of the invention involves obtaining tissue from living subjects, including liver tissue.

The use of molecular biological tools has become routine in forensic technology. For example, nucleic acid probes comprising all or at least part of the sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9 may be used

to determine the expression of a nucleic acid molecule in forensic/pathology specimens. Further, nucleic acid assays may be carried out by any means of conducting a transcriptional profiling analysis. In addition to nucleic acid analysis, forensic methods of the invention may target the proteins of the invention, particularly a protein comprising SEQ ID NO: 2, 4, 6, 8 or 10 to determine up- or down-regulation of the genes (Shiverick *et al.*, (1975) *Biochim Biophys Acta* 393:124-133).

Methods of the invention may involve treatment of tissues with collagenases or other proteases to make the tissue amenable to cell lysis (Semenov *et al.*, (1987) *Biull Eksp Biol Med* 104:113-116). Further, it is possible to obtain biopsy samples from different regions of the liver for analysis.

Assays to detect nucleic acid or protein molecules of the invention may be in any available format. Typical assays for nucleic acid molecules include hybridization or PCR based formats. Typical assays for the detection of proteins, polypeptides or peptides of the invention include the use of antibody probes in any available format such as *in situ* binding assays, etc. (see Harlow & Lane, Antibodies - A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988. In preferred embodiments, assays are carried-out with appropriate controls.

The above methods may also be used in other diagnostic protocols, including protocols and methods to detect disease states in other tissues or organs, for example in tissues in which expression of a nucleic acid molecule of the invention is detected.

Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following working examples therefore, specifically point out preferred embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.

## EXAMPLES

### Example 1a

#### Identification of Differentially Expressed LBFL302 mRNA in Hepatocellular Carcinoma

The patient tissue samples were derived from 10 Korean patients and classified into two groups of 5 patients each. One group consisted of patients who had been diagnosed with chronic viral hepatitis B (CH) and who later developed hepatic carcinomas (HCC). The patients in this group, three men and two women, ranged in age from 34-63. The second group of patients had been diagnosed with cirrhosis of the liver (LC). These people also later developed hepatic carcinomas (HCC). In this group of 4 men and one woman, the patients ranged in age from 40-62. For each patient, tissue was obtained from two areas of the liver to produce a set of biopsy samples. In the first patient group (cancer/hepatitis), samples were removed from liver tumors and from the non-cancerous surrounding area composed of inflamed tissue (inflammation due to hepatitis). In the second group (cancer/cirrhosis), liver tissue was removed from tumors and from the non-cancerous surrounding area composed of fibrotic tissue (areas of fibrosis due to cirrhosis). Histological analysis of each of the tissue samples was performed and samples were segregated into either non-cancerous or cancerous categories.

With minor modifications, the sample preparation protocol followed the Affymetrix GeneChip Expression Analysis Manual. Frozen tissue was first ground to powder using the Spex Certiprep 6800 Freezer Mill. Total RNA was then extracted using Trizol (Life Technologies). The total RNA yield for each sample (average tissue weight of 300 mg) was 200-500  $\mu$ g. Next, mRNA was isolated using the Oligotex mRNA Midi kit (Qiagen). Since the mRNA was eluted in a final volume of 400  $\mu$ l, an ethanol precipitation step was required to bring the concentration to 1  $\mu$ g/ $\mu$ l. Using 1-5  $\mu$ g of mRNA, double stranded cDNA was created using the SuperScript Choice system (Gibco-BRL). First strand cDNA synthesis was primed with a T7-(dT<sub>24</sub>) oligonucleotide. The cDNA was then phenol-chloroform extracted and ethanol precipitated to a final concentration of 1  $\mu$ g/ $\mu$ l.

From 2  $\mu$ g of cDNA, cRNA was synthesized according to standard procedures.



To biotin label the cRNA, nucleotides Bio-11-CTP and Bio-16-UTP (Enzo Diagnostics) were added to the reaction. After a 37 °C incubation for six hours, the labeled cRNA was cleaned up according to the Rneasy Mini kit protocol (Qiagen). The cRNA was then fragmented (5× fragmentation buffer: 200 mM Tris-Acetate (pH 8.1), 500 mM KOAc, 150 mM MgOAc) for thirty-five minutes at 94 °C.

55 µg of fragmented cRNA was hybridized on the Affymetrix Human Genome U95 and U133 set of arrays for twenty-four hours at 60 rpm in a 45 °C hybridization oven. The chips were washed and stained with Streptavidin Phycoerythrin (SAPE) (Molecular Probes) in Affymetrix fluidics stations. To amplify staining, SAPE solution was added twice with an anti-streptavidin biotinylated antibody (Vector Laboratories) staining step in between. Hybridization to the probe arrays was detected by fluorometric scanning (Hewlett Packard Gene Array Scanner). Following hybridization and scanning, the microarray images were analyzed for quality control, looking for major chip defects or abnormalities in hybridization signal. After all chips passed QC, the data was analyzed using Affymetrix Microarray Suite (v4.0), and LIMS (v1.5) for U95 or Affymetrix Microarray Suite (v5.0), and LIMS (v3.0) for U133.

Differential expression of genes between the cancerous and non-cancerous liver samples was determined by using Affymetrix human GeneChip sets, U95 and U133, with the following statistical methods. (1) For each gene, Affymetrix GeneChip average difference values for U95 were determined by Affymetrix Microarray Suite (v4.0), which also made "Absent" (=not detected), "Present" (=detected) or "Marginal" (=not clearly Absent or Present) calls for each GeneChip element. Signal values for U133 were determined by Affymetrix Microarray Suite (v5.0), which also made Absent, Present or Marginal calls. (2) Using the criteria of at least 10% present call in both cancerous and non-cancerous liver samples and at least 40% present call in either cancerous or non-cancerous liver sample groups, a gene set was selected for further analysis. (3) Based on the average difference values of U95 data, the gene set was split into two groups, a high expression group and low expression group. The high expression group contained genes with average difference values greater than or equal to 5 in both cancerous and non-cancerous samples. The remainder of the genes were included in the low

expression group. The average difference values were transformed to a logarithmic scale for the high expression group, but were not changed for the low expression group. For U133 data, all signal values were transformed to a logarithmic scale regardless of expression level. (4) The Analysis of Variance (ANOVA) method was used for data analysis (Steel et al., Principles and Procedures of Statistics: A Biometrical Approach, Third Ed., McGraw-Hill, 1997). Prior to the final analysis, a leave-one-out approach is used for outlier detection. One sample at a time was left out of the ANOVA analysis to determine whether or not omitting a specific sample from the analysis had any significant effect on the final result. If so, that particular sample was excluded from the final analysis. After outlier detection, a list of genes that are differentially expressed with a p-value of less than or equal to 0.05 was generated by ANOVA. Data from Affymetrix GeneChip U133 chip set was analyzed with a similar procedure. (5) Two additional criteria were used to reduce the number of genes in the gene list generated from U95. Firstly, geometric mean values were compared between the non-cancerous control group samples and the carcinoma disease group samples to obtain a set of genes showing at least 2.0-fold increases or decreases in expression level. Secondly, the ratio of the fold-change value and the p-value had to be 400 or greater.

Analysis of the chip data showed that the expression of the marker LBFL302 was significantly up-regulated (6.26-fold,  $p = 0.00116$  for U95; 7.87-fold,  $p = 0.000944$  for U133) in liver carcinoma samples compared to samples from cirrhotic liver tissue. Up-regulation (2.76-fold,  $p > 0.05$  for U95; 4.64-fold,  $p = 0.0115$  for U133) was also observed in liver carcinoma samples compared to tissue samples from inflamed liver tissue (biopsies from areas of inflammation in chronic hepatitis patients). These data indicate that up-regulation of LBFL302 may be diagnostic for liver cancer in people with cirrhosis and may also be diagnostic for liver cancer in people with chronic hepatitis.

The expression level of LBFL302 (SEQ ID NO: 1 or 3) can be measured by chip sequence fragment nos. 51263\_at and 226936\_at on Affymetrix GeneChips® U95 and U133, respectively. The expression levels of 51263\_at and 226936\_at in various malignant neoplasms, compared to normal control tissues, are shown in Table 1a, where the fold-change and the direction of the change (up- or down-regulation) are also

indicated. A fold-change greater than 1.5 was considered to be significant.

Table 1a

Atty ID	Tissue	Disease	Morphology	Fold Change	Dir	T-Stat
51263_at	BLADDER, NOS	MALIGNANT NEOPLASM OF BLADDER, NOS	TRANSITIONAL CELL CARCINOMA, NOS	1.9	Up	3.9
226936_at	BREAST, NOS	MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	INFILTRATING DUCT CARCINOMA	1.8	Up	3.6
51263_at		MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	MUCINOUS ADENOCARCINOMA	-1.7	Down	-3.5
226936_at	CERVIX, NOS	MALIGNANT NEOPLASM OF UTERINE CERVIX	SQUAMOUS CELL CARCINOMA, NOS	3.5	Up	4.1
226936_at	COLON, NOS	MALIGNANT NEOPLASM OF COLON, NOS	ADENOCARCINOMA, NOS	2.2	Up	7.8
226936_at	ENDOMETRIUM, NOS	MALIGNANT NEOPLASM OF ENDOMETRIUM	MULLERIAN MIXED TUMOR	2.4	Up	2.6
226936_at	KIDNEY, NOS	MALIGNANT NEOPLASM OF KIDNEY, NOS	WILMS' TUMOR	14.3	Up	3.2
226936_at	LIVER, NOS	SECONDARY MALIGNANT NEOPLASM OF LIVER, NOS	ADENOCARCINOMA, NOS	5.6	Up	5.7
226936_at	LUNG, NOS	MALIGNANT NEOPLASM OF LUNG, NOS	SQUAMOUS CELL CARCINOMA, NOS	4.0	Up	6.3
226936_at		MALIGNANT NEOPLASM OF LUNG, NOS	ADENOCARCINOMA, NOS	1.7	Up	2.2
51263_at	MYOMETRIUM, NOS	SECONDARY MALIGNANT NEOPLASM OF MYOMETRIUM	MULLERIAN MIXED TUMOR	2.3	Up	4.6
226936_at	OVARY, NOS	MALIGNANT NEOPLASM OF OVARY	ADENOCARCINOMA, NOS	5.7	Up	2.3
226936_at		MALIGNANT NEOPLASM OF OVARY	PAPILLARY SEROUS ADENOCARCINOMA	4.8	Up	3.9
226936_at	PANCREAS, NOS	MALIGNANT NEOPLASM OF PANCREAS, NOS	ADENOCARCINOMA, NOS	3.2	Up	2.2
226936_at	PROSTATE, NOS	MALIGNANT NEOPLASM OF PROSTATE	ADENOCARCINOMA, NOS	-1.6	Down	-5.6
226936_at	RECTUM, NOS	MALIGNANT NEOPLASM OF RECTUM	ADENOCARCINOMA, NOS	2.1	Up	6.5
226936_at	SKIN, NOS	MALIGNANT NEOPLASM OF SKIN, NOS	SQUAMOUS CELL CARCINOMA, NOS	2.8	Up	3.1
226936_at		MALIGNANT NEOPLASM OF SKIN, NOS	BASAL CELL CARCINOMA, NOS	1.7	Up	2.9
51263_at	SMALL INTESTINE, NOS	MALIGNANT LYMPHOMA, NOS OF UNSPECIFIED, EXTRANODAL OR SOLID ORGAN SITE	MALIGNANT LYMPHOMA, NOS	3.0	Up	3.1
226936_at	SOFT TISSUES, NOS	SECONDARY MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUES, NOS	SQUAMOUS CELL CARCINOMA, NOS	2.5	Up	3.2
226936_at	SPLEEN, NOS	CHRONIC MYELOID LEUKEMIA WITHOUT MENTION OF REMISSION	CHRONIC MYELOID LEUKEMIA	6.6	Up	16.1
226936_at	STOMACH, NOS	MALIGNANT NEOPLASM OF STOMACH, NOS	ADENOCARCINOMA, NOS	2.3	Up	4.6
226936_at		MALIGNANT NEOPLASM OF STOMACH, NOS	SIGNET RING CELL CARCINOMA	1.9	Up	2.9

Table 2 summarizes the differential expression data collected from experiments using Affymetrix GeneChips by tissue type. The chips were scanned and the data analyzed by the GX Scan algorithm, which is described in related applications 60/331,182, 60/388,745 and 60/390,608, all entitled "An Automated Computer-based Algorithm for Organizing and Mining Gene Expression Data Derived from Biological Samples with Complex Clinical Attributes," and all of which are herein incorporated by reference in their entirety.

## 10 Table 2

LBFL302 is up-regulated in certain types of the following malignant neoplasms with a fold change of 1.5 and above:

	<u>51263_at From U95 data</u>	<u>226936_at From U133 data</u>
1. Bladder	UP	---
2. Breast		
(Infiltrating duct carcinoma)	UP	UP
3. Cervix	UP	UP
4. Colon	UP	UP
5. Kidney	UP	UP
6. Liver	UP	UP
7. Lung	UP	UP
8. Myometrium	UP	---
9. Ovary	UP	UP
10. Pancreas	UP	UP
11. Rectum	UP	UP
12. Skin	UP	UP
13. Small Intestine	UP	---
14. Soft tissues	UP	UP
15. Spleen	UP	UP
16. Stomach	UP	UP

15 The GeneChip expression results, determined by sample binding to chip sequence fragment no. 51263\_at, were validated by quantitative RT-PCR (Q-RT-PCR) using the Taqman® assay (Perkin-Elmer). PCR primers designed from the sequence information file of the specific Affymetrix fragment (51263\_at) were used in the assay. The target gene in each RNA sample (ten ng of total RNA) was assayed relative to an exogenously spiked reference gene. For this purpose, the tetracycline resistance gene was used as the exogenously added spike. This approach provides the relative expression as measured by cycle threshold (Ct) value of the target mRNA relative to a

constant amount of Tet spike Ct values. The sample panel included liver cirrhosis (LC), chronic hepatitis (CH) and hepatocellular carcinoma (HCC) tissue RNAs that were analyzed on U95 GeneChips. In addition, several new samples that were not analyzed on the GeneChip were used for the expression validations by Q-RT-PCR. The Q-RT-PCR data confirms the up-regulation of LBFL302 observed in HCC, compared to LC or CH biopsy samples.

### Example 1b

#### Identification of Differentially Expressed LBFL303 mRNA in Hepatocellular Carcinoma

The patient tissue samples were derived from 19 Korean patients and classified into two groups. One group consisted of nine patients who had been diagnosed with chronic viral hepatitis B (CH) and who later developed hepatic carcinomas (HCC). The patients in this group, five men and four women, ranged in age from 34-65. The second group, of ten patients, had been diagnosed with cirrhosis of the liver (LC). These people also later developed hepatic carcinomas (HCC). In this group of eight men and two women, the patients ranged in age from 37-62. The same procedures as in the above Example 1a were then carried out for each patient.

Analysis of the data from U95 chips showed that expression of the marker corresponding to SEQ ID NO: 5, 7 or 9 was significantly up-regulated (9.34-fold,  $p$ -value =  $1.44 \times 10^{-4}$ ) in liver carcinoma samples compared to samples from cirrhotic liver tissue. Data from U133 chips showed that expression of SEQ ID NO: 5 or 7 was also significantly up-regulated in liver carcinoma samples compared to samples from cirrhotic liver tissue (2.60-fold,  $p$ -value =  $3.63 \times 10^{-2}$ ) and compared to samples from inflamed liver tissue (5.69-fold,  $p = 8.99 \times 10^{-4}$  for U95) (biopsies from areas of inflammation in chronic hepatitis patients). These data indicate that up-regulation of SEQ ID NOS: 5, 7 and 9 may be diagnostic for liver cancer in people and, in particular, patients with cirrhosis or chronic hepatitis.

The expression level of LBFL303 clones GE6, MB5 or IE4 (SEQ ID NOS: 5, 7 or 9, respectively) can be measured by chip sequence fragment nos. 46690\_at (U95 chip) and 219175\_at and 224931\_at (U133 chip) on Affymetrix GeneChips®. Differential

expression data were collected from experiments using Affymetrix GeneChips® by tissue type and were analyzed by the GX Scan algorithm, which is described in related applications 60/331,182, 60/388,745 and 60/390,608, all entitled “An Automated Computer-based Algorithm for Organizing and Mining Gene Expression Data Derived from Biological Samples with Complex Clinical Attributes,” and all of which are herein  
5 incorporated by reference in their entirety. The expression levels of -46690\_at, 219175\_at and 224931\_at in various malignant neoplasms, compared to normal control tissues, are shown in Table 1, where the fold-change and the direction of the change (up- or down-regulation) are also indicated. A fold-change greater than 1.5 was considered  
10 to be significant.

Table 1b

Affy ID	Tissue	Disease	Morphology	Fold Change	Dir.	T-Stat
46690_at	BREAST, NOS	MALIGNANT NEOPLASM OF FEMALE BREAST, NOS	INFILTRATING DUCT AND LOBULAR CARCINOMA	-1.7	Down	-5.5
46690_at	CERVIX, NOS	MALIGNANT NEOPLASM OF UTERINE CERVIX	SQUAMOUS CELL CARCINOMA, NOS	-1.7	Down	-4.5
224931_at	KIDNEY, NOS	MALIGNANT NEOPLASM OF KIDNEY, NOS	WILMS' TUMOR	1.6	Up	6.3
46690_at	OVARY, NOS	MALIGNANT NEOPLASM OF OVARY	MUCINOUS CYSTADENOCARCINOMA, NOS	-1.5	Down	-2.9
219175_s_at		MALIGNANT NEOPLASM OF OVARY	MULLERIAN MIXED TUMOR	-1.6	Down	-11.3
219175_s_at	PANCREAS, NOS	MALIGNANT NEOPLASM OF ISLETS OF LANGERHANS	ISLET CELL CARCINOMA	-2.2	Down	-9.2
46690_at		MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUES, NOS	FIBROUS HISTIOCYTOMA, MALIGNANT	-1.6	Down	-3.2
46690_at	SOFT TISSUES, NOS	MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUES, NOS	LIPOSARCOMA, NOS	-1.6	Down	-2.6
219175_s_at		MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUES, NOS	LIPOSARCOMA, NOS	-1.6	Down	-2.5
46690_at	TESTIS, NOS	MALIGNANT NEOPLASM OF TESTIS, NOS	MIXED GERM CELL TUMOR	-2.2	Down	-2.8
46690_at		MALIGNANT NEOPLASM OF TESTIS, NOS	SEMINOMA, NOS	-2.5	Down	-2.3
224931_at		MALIGNANT NEOPLASM OF TESTIS, NOS	MIXED GERM CELL TUMOR	-1.7	Down	-2.3
224931_at	THYROID GLAND, NOS	MALIGNANT LYMPHOMA, NOS OF UNSPECIFIED, EXTRANODAL OR SOLID ORGAN SITE	MALIGNANT LYMPHOMA, NOS	-1.7	Down	-4.4

The GeneChip expression results, determined by sample binding to chip sequence fragment no. 46690\_at, were validated by quantitative RT-PCR (Q-RT-PCR) using the Taqman® assay (Perkin-Elmer), as in the above Example 1a.

The Q-RT-PCR data confirms the up-regulation of the genes corresponding to LBFL303 clones GE6, MB5 and IE4 observed in HCC, compared to LC or CH biopsy samples.

## 5 Example 2

### Cloning of Full Length human cDNAs Corresponding to Differentially Expressed mRNA Species

The full length cDNA having SEQ ID NO: 1, 3, 5, 7 or 9 was obtained by the oligo-pulling method. Briefly, a gene-specific oligo was designed based on the  
10 sequence of SEQ ID NO: 1, 3, 5, 7 or 9. The oligo was labeled with biotin and used to hybridize with 2 µg of single strand plasmid DNA (cDNA recombinants) from a fully differentiated stomach adenocarcinoma library (NCI CGAP Gas 4) following the procedures of Sambrook *et al.* The hybridized cDNAs were separated by streptavidin-conjugated beads and eluted by heating. The eluted cDNA was converted  
15 to double strand plasmid DNA and used to transform *E. coli* cells (DH10B) and the longest cDNA was screened. After positive selection was confirmed by PCR using gene-specific primers, the cDNA clone was subjected to DNA sequencing.

The nucleotide sequence of the full-length human cDNAs corresponding to the differentially regulated mRNA detected above is set forth in SEQ ID NOS: 1, 3, 5, 7 and  
20 9. The cDNA of SEQ ID NO: 1 comprises 578 base pairs (531 base pairs and a polyA tail), and the cDNA of SEQ ID NO: 3 comprises 531 base pairs (515 base pairs and a polyA tail). The cDNA of SEQ ID NO: 5 comprises 2067 base pairs (2040 base pairs and a polyA tail), the cDNA of SEQ ID NO: 7 comprises 2178 base pairs (2162 base pairs and a polyA tail), and the cDNA of SEQ ID NO: 9 comprises 1616 bases pairs  
25 (1598 base pairs and a polyA tail).

An open reading frame within the cDNA nucleotide sequence of SEQ ID NO: 1, at nucleotides 155-418 (155-421 including the stop codon), encodes a protein of 88 amino acids. The amino acid sequence corresponding to a predicted protein encoded by SEQ ID NO: 1 is set forth in SEQ ID NO: 2.

30 An open reading frame within the cDNA nucleotide sequence of SEQ ID NO: 3,



at nucleotides 139-402 (139-405 including the stop codon), also encodes a protein of 88 amino acids. The amino acid sequence corresponding to a predicted protein encoded by SEQ ID NO: 3 is set forth in SEQ ID NO: 4. The protein sequence of SEQ ID NO: 4 is identical to that of SEQ ID NO: 2, except for the amino acid at position 28 (arginine in  
5 SEQ ID NO: 2, but leucine in SEQ ID NO: 4, caused by a G->T point mutation at nucleotide position no. 237 in SEQ ID NO: 1 and 221 in SEQ ID NO: 3), although the nucleic acid sequences encoding these proteins differ upstream of the coding region.

SEQ ID NOS: 2 and 4 are weakly similar to histone-like transcription factor (CBF/NF-Y) and the archaeal histone signature. In addition, these amino acid  
10 sequences are weakly similar to the bacterial regulatory protein lysR family helix-turn-helix signature. This signature contains three domains. The amino acid sequences of SEQ ID NO:2 and SEQ ID NO: 4 are 22% identical to the two domains at the C-terminus.

An open reading frame within the cDNA nucleotide sequence of SEQ ID NO: 5 (GE6), at nucleotides 32-1384 (32-1387 including the stop codon), encodes a protein of  
15 451 amino acids. The amino acid sequence corresponding to the protein encoded by SEQ ID NO: 5 is set forth in SEQ ID NO: 6.

An open reading frame within the cDNA nucleotide sequence of SEQ ID NO: 7 (MB5), at nucleotides 41-1501 (41-1504 including the stop codon), encodes a protein of 487 amino acids. The amino acid sequence corresponding to the protein encoded by  
20 SEQ ID NO: 7 is set forth in SEQ ID NO: 8. The protein sequence of SEQ ID NO: 8 is identical to that of SEQ ID NO: 6, except for an insertion of 36 amino acids toward the amino terminus (see multiple sequence alignment below).

An open reading frame within the cDNA nucleotide sequence of SEQ ID NO: 9 (IE4), at nucleotides 31-1551 (31-1554 including the stop codon), encodes a protein of  
25 507 amino acids. The amino acid sequence corresponding to the protein encoded by SEQ ID NO: 9 is set forth in SEQ ID NO: 10. The protein corresponding to SEQ ID NO: 10 is identical to that of SEQ ID NO: 8 for the first 456 amino acids, although the remainders of the proteins have no homology (see multiple sequence alignment below).

## Multiple amino acid sequence alignment for GE6, MB5 and IE4

	1		50
LBFL303_GE6.pep	MDGTETRQRR LDSCGKPGEL GLPHPLSTGG LPVASEDGAL RAPESQSVTP		
LBFL303_MB5.pep	MDGTETRQRR LDSCGKPGEL GLPHPLSTGG LPVASEDGAL RAPESQSVTP		
LBFL303_IE4.pep	MDGTETRQRR LDSCGKPGEL GLPHPLSTGG LPVASEDGAL RAPESQSVTP		
Consensus	MDGTETRQRR LDSCGKPGEL GLPHPLSTGG LPVASEDGAL RAPESQSVTP		
	51		100
LBFL303_GE6.pep	KPLETEPSRE TAWSIGLQVT VPFMFAGLGL SWAGMLLDYF Q.....		
LBFL303_MB5.pep	KPLETEPSRE TAWSIGLQVT VPFMFAGLGL SWAGMLLDYF QHWPVFVEVK		
LBFL303_IE4.pep	KPLETEPSRE TAWSIGLQVT VPFMFAGLGL SWAGMLLDYF QHWPVFVEVK		
Consensus	KPLETEPSRE TAWSIGLQVT VPFMFAGLGL SWAGMLLDYF QHWPVFVEVK		
	101		150
LBFL303_GE6.pep	.....ANT GQIDDPQEQH RVISSNLALI		
LBFL303_MB5.pep	DLTLVPPPLV GLKGNLEMTL ASRLSTAANT GQIDDPQEQH RVISSNLALI		
LBFL303_IE4.pep	DLTLVPPPLV GLKGNLEMTL ASRLSTAANT GQIDDPQEQH RVISSNLALI		
Consensus	DLTLVPPPLV GLKGNLEMTL ASRLSTAANT GQIDDPQEQH RVISSNLALI		
	151		200
LBFL303_GE6.pep	QVQATVVGLL AAVAALLGV VSREEVDVAK VELLCASSVL TAFLAALFALG		
LBFL303_MB5.pep	QVQATVVGLL AAVAALLGV VSREEVDVAK VELLCASSVL TAFLAALFALG		
LBFL303_IE4.pep	QVQATVVGLL AAVAALLGV VSREEVDVAK VELLCASSVL TAFLAALFALG		
Consensus	QVQATVVGLL AAVAALLGV VSREEVDVAK VELLCASSVL TAFLAALFALG		
	201		250
LBFL303_GE6.pep	VLMVCIVIGA RKLGVNPDNI ATPIAASLGD LITLSILALV SFFFYRHKDS		
LBFL303_MB5.pep	VLMVCIVIGA RKLGVNPDNI ATPIAASLGD LITLSILALV SFFFYRHKDS		
LBFL303_IE4.pep	VLMVCIVIGA RKLGVNPDNI ATPIAASLGD LITLSILALV SFFFYRHKDS		
Consensus	VLMVCIVIGA RKLGVNPDNI ATPIAASLGD LITLSILALV SFFFYRHKDS		
	251		300
LBFL303_GE6.pep	RYLTPLVCLS FAALTPVWVL IAKQSPPIVK ILKFGWFPII LAMVISSFGG		
LBFL303_MB5.pep	RYLTPLVCLS FAALTPVWVL IAKQSPPIVK ILKFGWFPII LAMVISSFGG		
LBFL303_IE4.pep	RYLTPLVCLS FAALTPVWVL IAKQSPPIVK ILKFGWFPII LAMVISSFGG		
Consensus	RYLTPLVCLS FAALTPVWVL IAKQSPPIVK ILKFGWFPII LAMVISSFGG		
	301		350
LBFL303_GE6.pep	LILSKTVSKQ QYKGMAIFTP VICGVGGNLV AIQTSRISTY LHMWSAPGVL		
LBFL303_MB5.pep	LILSKTVSKQ QYKGMAIFTP VICGVGGNLV AIQTSRISTY LHMWSAPGVL		
LBFL303_IE4.pep	LILSKTVSKQ QYKGMAIFTP VICGVGGNLV AIQTSRISTY LHMWSAPGVL		
Consensus	LILSKTVSKQ QYKGMAIFTP VICGVGGNLV AIQTSRISTY LHMWSAPGVL		
	351		400
LBFL303_GE6.pep	PLQMKKFWPN PCSTFCTSEI NSMSARVLLL LVVPGHLIFF YIIYLVEGQS		
LBFL303_MB5.pep	PLQMKKFWPN PCSTFCTSEI NSMSARVLLL LVVPGHLIFF YIIYLVEGQS		
LBFL303_IE4.pep	PLQMKKFWPN PCSTFCTSEI NSMSARVLLL LVVPGHLIFF YIIYLVEGQS		
Consensus	PLQMKKFWPN PCSTFCTSEI NSMSARVLLL LVVPGHLIFF YIIYLVEGQS		
	401		450
LBFL303_GE6.pep	VINSQTFVVL YLLAGLIQVT ILLYLAEMV RLTWHQALDP DNHCIPLYLTG		
LBFL303_MB5.pep	VINSQTFVVL YLLAGLIQVT ILLYLAEMV RLTWHQALDP DNHCIPLYLTG		
LBFL303_IE4.pep	VINSQTFVVL YLLAGLIQVT ILLYLAEMV RLTWHQALDP DNHCIPLYLTG		
Consensus	VINSQTFVVL YLLAGLIQVT ILLYLAEMV RLTWHQALDP DNHCIPLYLTG		
	451		500
LBFL303_GE6.pep	LGDLLGTGLL ALCFFTDWLL KSKAELGGIS ELASGPP*--		
LBFL303_MB5.pep	LGDLLGTGLL ALCFFTDWLL KSKAELGGIS ELASGPP*--		
LBFL303_IE4.pep	LGDLLGSSSV GHTAAVPRRC TAPGHWGLIQ PFICTQHLIV SLLSPYPPFC		
Consensus	LGDLLGTGLL ALCFFTDWLL KSKAELGGIS ELASGPP*--		
	501		
LBFL303_GE6.pep	-----		
LBFL303_MB5.pep	-----		
LBFL303_IE4.pep	LLAKTSI*		
Consensus	-----		

The LBFL303 clones also exhibit partial homology to a mouse homologue (GenBank Accession No. XM\_132686). SEQ ID NO: 5 shows 44% identity over the entire contiguous sequence and 68% identity within the open reading frame, while SEQ

ID NO: 7 shows 46% identity over the entire contiguous sequence and 69% identity within the open reading frame. SEQ ID NO: 9 shows 61% identity over the entire contiguous sequence and 64% identity within the open reading frame to the mouse nucleic acid sequence.

5        SEQ ID NOS: 6, 8 and 10 contain a divalent cation transporter signature that has two domains. SEQ ID NOS: 6 and 8 contain both domains (at amino acid positions 85-205 and 282-428 in SEQ ID NO: 6, and at amino acid positions 105-241 and 318-464 in SEQ ID NO: 8), although SEQ ID NO: 10 contains only the N-terminal domain (from amino acid residues 105-241). In addition, SEQ ID NOS: 6, 8 and 10 contain a  
10        peroxidase-active site at amino acid positions 390-401 in SEQ ID NO: 6 and at amino acid positions 426-437 in SEQ ID NOS: 8 and 10.

Figures 1, 2, 3, 4 and 5 show the results of a hydrophobicity analysis of the amino acid sequence of SEQ ID NOS: 2, 4, 6, 8 and 10. Hydrophilic regions may be used to produce antigenic peptides, as described above.

15        Analysis by Northern blot was performed to determine the size of the mRNA transcripts that correspond to SEQ ID NOS: 1, 3, 5, 7 and 9. Northern blots containing total RNAs from various human tissues were used (ClonTech), and each of clone BC7 (SEQ ID NO: 3), clone GE6 (SEQ ID NO: 5), clone MB5 (SEQ ID NO: 7), clone IE4 (SEQ ID NO: 9) was radioactively labeled by the random primer method and used to  
20        probe the blots. The blots were hybridized in Church and Gilbert buffer at 65 °C and washed with 0.1X SSC containing 0.1% SDS at room temperature. The Northern blots show a single transcript for each LBFL302 and 303 gene, which is approximately 0.65 kb and 2.45 kb in size. This corresponds to the size of the insert in clones BC7 and BC4 (SEQ ID NOS: 3 and 1), 0.531 kb and 0.578 kb, respectively, and 2.2 kb for GE6,  
25        2.3 kb for MB5, and 1.8 kb for IE4, SEQ ID NOS: 5, 7 and 9, respectively.

To examine the expression of SEQ ID NO: 1, 3, 5, 7 or 9 in various normal tissues, an electronic Northern blot (e-Northern) was prepared as follows. Using the chips and the procedures in Example 1, mRNA from a panel of 46 normal tissues, as listed in Table 3, was hybridized to Affymetrix U95 human GeneChips. The results of these experiments  
30        are shown in Table 3. For each tissue type, the number of samples that are called

present or absent are indicated, together with the total number of samples in that sample set. In addition, the median value and the 25<sup>th</sup> and 75<sup>th</sup> percentiles in each tissue type are listed. Interestingly, although this gene is up-regulated in liver cancer, expression of LBFL302 and 303 could not be detected in most normal liver samples. This observation indicates that LBFL302 and 303 may be used as a diagnostic agent or marker to detect liver cancer or to differentiate hepatocellular carcinoma from cirrhotic liver tissue, as discussed below. Expression levels of LBFL302 appeared to be highest in the thymus, followed by organs of the reproductive system (testis, endometrium, myometrium, uterus, cervix and breast) and of the digestive system (esophagus, rectum, colon and appendix). Expression levels of LBFL303 appeared to be highest in the brain (cerebellum, frontal cortex, temporal cortex and hippocampus) and in organs of the reproductive system (testis, endometrium, myometrium, uterus, cervix and breast), but expression could be detected at lower levels in most other tissues. Expression in the liver was the lowest.

Table 3a- e-Northern Table for 51263\_at: LBFL302 Gene Expression in Normal Tissues

Global Present Freq.	Tissue	Present	Absent	Lower 25%	Median	Upper 75%
0.7176						
	Adipose	26 of 32	6 of 32	32.78	40.25	56.11
	Adrenal Gland	5 of 12	7 of 12	10.18	28.24	42.42
	Appendix	3 of 3	0 of 3	65.56	75.82	78.15
	Artery	3 of 3	0 of 3	39.18	43.53	48.12
	Bladder	5 of 5	0 of 5	49.95	81.92	89.71
	Bone	3 of 3	0 of 3	73.57	112.71	113.59
	Breast	76 of 80	4 of 80	56.53	79.61	107.84
	Cerebellum	1 of 5	4 of 5	10.58	16.98	17.79
	Cervix	96 of 101	5 of 101	75.45	102.71	139.70
	Colon	147 of 151	4 of 151	72.44	107.19	149.44
	Cortex Frontal Lobe	2 of 7	5 of 7	11.01	17.48	21.95
	Cortex Temporal Lobe	0 of 3	3 of 3	-1.09	10.90	11.83
	Duodenum	58 of 61	3 of 61	57.59	72.35	94.63
	Endometrium	21 of 21	0 of 21	123.36	151.44	185.97
	Esophagus	26 of 27	1 of 27	98.53	127.38	167.07
	Fallopian Tube	46 of 51	5 of 51	37.81	52.34	94.69
	GallBladder	2 of 8	6 of 8	13.23	32.72	39.09
	Heart	1 of 3	2 of 3	8.24	13.13	15.87
	Hippocampus	2 of 5	3 of 5	17.28	19.47	31.10
	Kidney	24 of 86	62 of 86	8.63	14.36	20.22
	Larynx	4 of 4	0 of 4	40.57	97.82	163.75
	Left Atrium	30 of 141	111 of 141	11.25	14.57	19.93
	Left Ventricle	0 of 15	15 of 15	4.77	8.67	12.80
	Liver	10 of 34	24 of 34	2.08	10.42	19.94
	Lung	62 of 93	31 of 93	23.04	35.46	55.34
	Lymph Node	10 of 11	1 of 11	58.47	85.56	98.77
	Muscles	9 of 39	30 of 39	9.03	16.64	27.86
	Myometrium	105 of 106	1 of 106	123.43	180.91	216.99
	Omentum	14 of 15	1 of 15	46.67	67.85	151.98
	Ovary	49 of 74	25 of 74	24.22	34.54	55.81
	Pancreas	2 of 34	32 of 34	-2.88	6.00	14.34
	Placenta	3 of 5	2 of 5	28.65	40.79	53.18
	Prostate	30 of 32	2 of 32	44.39	59.04	73.73
	Rectum	42 of 43	1 of 43	97.69	133.62	173.02
	Right Atrium	34 of 169	135 of 169	9.78	14.77	19.39
	Right Ventricle	21 of 160	139 of 160	4.93	10.56	18.22
	Skin	50 of 59	9 of 59	44.51	64.27	93.29
	Small Intestine	60 of 68	8 of 68	41.12	70.61	103.24
	Soft Tissues	4 of 6	2 of 6	26.64	61.11	115.92
	Spleen	22 of 31	9 of 31	26.94	39.23	52.19
	Stomach	34 of 47	13 of 47	22.49	41.88	80.51
	Testis	5 of 5	0 of 5	137.44	236.97	359.92
	Thymus	71 of 71	0 of 71	261.31	322.22	358.16
	Thyroid Gland	6 of 18	12 of 18	10.27	15.12	31.99
	Uterus	58 of 58	0 of 58	88.62	140.06	190.83
	WBC	12 of 40	28 of 40	10.23	15.37	24.59

Table 3b- e-Northern Table for 46690\_at: LBFL303 Gene Expression in Normal Tissues

Global Present Freq.	Tissue	Present	Absent	Lower 25%	Median	Upper 75%
0.6295						
	Adipose	21 of 32	11 of 32	176.42	227.48	291.00
	Adrenal Gland	10 of 12	2 of 12	195.93	286.51	364.93
	Appendix	2 of 3	1 of 3	59.10	61.20	71.28
	Artery	3 of 3	0 of 3	257.57	268.59	334.19
	Bladder	4 of 5	1 of 5	222.21	236.51	310.37
	Bone	2 of 3	1 of 3	241.64	263.23	269.74
	Breast	74 of 80	6 of 80	208.22	279.85	332.28
	Cerebellum	5 of 5	0 of 5	333.02	348.16	421.84
	Cervix	88 of 101	13 of 101	212.62	292.96	344.12
	Colon	70 of 151	81 of 151	63.11	98.21	142.28
	Cortex Frontal Lobe	7 of 7	0 of 7	293.14	313.78	323.67
	Cortex Temporal Lobe	3 of 3	0 of 3	255.54	260.80	339.41
	Duodenum	31 of 61	30 of 61	86.34	113.58	143.09
	Endometrium	18 of 21	3 of 21	243.49	259.81	299.21
	Esophagus	17 of 27	10 of 27	120.68	166.05	207.75
	Fallopian Tube	45 of 51	6 of 51	236.80	296.76	358.36
	GallBladder	8 of 8	0 of 8	250.23	277.49	328.73
	Heart	2 of 3	1 of 3	128.08	129.40	139.86
	Hippocampus	5 of 5	0 of 5	216.82	302.36	337.49
	Kidney	53 of 86	33 of 86	155.75	202.37	235.42
	Larynx	3 of 4	1 of 4	189.07	222.38	268.94
	Left Atrium	75 of 141	66 of 141	130.83	173.47	220.14
	Left Ventricle	8 of 15	7 of 15	117.45	175.84	208.91
	Liver	5 of 34	29 of 34	8.65	33.49	55.39
	Lung	52 of 93	41 of 93	115.09	167.11	232.69
	Lymph Node	8 of 11	3 of 11	119.03	167.95	223.28
	Muscles	32 of 39	7 of 39	147.91	200.14	226.77
	Myometrium	98 of 106	8 of 106	248.04	328.05	407.02
	Omentum	8 of 15	7 of 15	88.63	179.55	196.14
	Ovary	71 of 74	3 of 74	306.34	384.95	435.31
	Pancreas	10 of 34	24 of 34	78.67	128.72	162.20
	Placenta	1 of 5	4 of 5	79.06	108.81	112.22
	Prostate	23 of 32	9 of 32	181.76	193.51	230.41
	Rectum	28 of 43	15 of 43	113.19	126.40	167.84
	Right Atrium	82 of 169	87 of 169	134.58	166.54	208.73
	Right Ventricle	100 of 160	60 of 160	122.83	165.44	216.16
	Skin	49 of 59	10 of 59	185.75	236.37	297.31
	Small Intestine	33 of 68	35 of 68	69.62	109.95	142.30
	Soft Tissues	5 of 6	1 of 6	186.44	214.50	260.89
	Spleen	22 of 31	9 of 31	149.56	184.29	215.47
	Stomach	20 of 47	27 of 47	77.44	114.84	158.63
	Testis	5 of 5	0 of 5	396.28	429.08	448.94

Global Present Freq.	Tissue	Present	Absent	Lower 25%	Median	Upper 75%
	Thymus	70 of 71	1 of 71	296.44	348.71	400.48
	Thyroid Gland	13 of 18	5 of 18	228.07	310.09	350.55
	Uterus	53 of 58	5 of 58	249.90	318.35	361.58
	WBC	15 of 40	25 of 40	68.93	94.14	122.44

## INDUSTRIAL APPLICABILITY

### 5 Example 3

#### Detection of LBFL302 and 303 mRNA for Liver Cancer Screening

The expression level of mRNA corresponding to SEQ ID NO: 1, 3, 5, 7 or 9 is determined in liver tissue biopsy samples, as described in Example 1, *i.e.*, by screening mRNA samples on a GeneChip, or as described in Example 2, *i.e.*, by screening mRNA samples on a Northern blot. Alternatively, samples from non-liver hyperplastic tissues in malignant or non-malignant states may also be analyzed. Liver tissue samples from patients with liver cancer and from normal subjects may be used as positive and negative controls. Using any means of assaying gene expression, a level of expression higher than that of the normal control is indicative of liver cancer or a likelihood of developing liver cancer.

Although the present invention has been described in detail with reference to examples above, it is understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims. All cited patents, patent applications and publications referred to in this application are herein incorporated by reference in their entirety.